As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the ...
Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data ...
Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support ...
Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with ...
The past weekend has seen a number of major data presentations at the American Diabetes Association (ADA) conference 2026.
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Repatha is not a drug where Amgen has pricing power to absorb such exposure. The Denmark exit should be read as a rational, if disruptive, response to that specific vulnerability — not as the ...
Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results